

REMARKS

No claims have been canceled or added herein. Claim 4 has been amended herein.  
Therefore, claims 1-11 are under active consideration.

It is respectfully submitted that the present application is in condition for allowance. Prompt and favorable action is earnestly solicited.

If there are any fees due in connection with the filing of this paper that are not accounted for, the Examiner is authorized to charge the fees to our Deposit Account No. 11-1755. If a fee is required for an extension of time under 37 C.F.R. 1.136 that is not accounted for already, such an extension of time is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Kriegsman & Kriegsman

By: Edullgn  
Edward M. Kriegsman  
Reg. No. 33,529  
665 Franklin Street  
Framingham, MA 01702  
(508) 879-3500

Dated: August 20, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box PCT, Commissioner for Patents, Washington, D.C. 20231 on August 20, 2002

Edullgn  
Edward M. Kriegsman  
Reg. No. 33,529  
Dated: August 20, 2002

10099039 . 092244

MARKED-UP AMENDED CLAIM 4

4. (Amended) 1-Aziridine-1-hydroxyiminomethyl derivatives pursuant to [one of the preceding claims] claim 1, characterized by the fact that  $R_1$  and  $R_2$  independently of one another represent hydrogen atoms or a  $-\text{CONH}_2$  group.